Sugi Predict

Sugi Predict / Targets / BCL2

BCL2

Apoptosis regulator Bcl-2 · P10415 · BCL2 on Sugi Atlas →

124,362 patent compounds predicted against BCL2, 92,293 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Gossypol Gossypol (SCHEMBL3939) 1.00 11/20
SCHEMBL206442 SCHEMBL206442 0.55 11/20
Abt 737 Abt 737 (SCHEMBL158942) 1.00 9/20
Abt 737 Abt 737 (SCHEMBL170470) 1.00 9/20
SCHEMBL158040 SCHEMBL158040 1.00 8/20
SCHEMBL158041 SCHEMBL158041 1.00 8/20
SCHEMBL161869 SCHEMBL161869 0.63 8/20
SCHEMBL214415 SCHEMBL214415 0.41 8/20
SCHEMBL78583 SCHEMBL78583 0.55 7/20
SCHEMBL78662 SCHEMBL78662 0.55 7/20
SCHEMBL110590 SCHEMBL110590 0.42 6/20
SCHEMBL1345 SCHEMBL1345 0.41 6/20
SCHEMBL219876 SCHEMBL219876 0.48 5/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL219199) 0.48 5/20
Athraquinones A Athraquinones A (SCHEMBL18614) 1.00 4/20
Epigalocatechin Gallate Epigalocatechin Gallate (SCHEMBL35258) 1.00 4/20
Epicatechin Gallate Epicatechin Gallate (SCHEMBL39046) 1.00 4/20
Epicatechin Gallate Epicatechin Gallate (SCHEMBL39047) 1.00 4/20
Gallocatechin Gallate Gallocatechin Gallate (SCHEMBL49461) 1.00 4/20
Catechin Gallate Catechin Gallate (SCHEMBL145289) 1.00 4/20

Clinical trials — most relevant to BCL2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Clinical Study Evaluating the Anticancer Effect of Pentoxiphylline in Patients With Metastatic Colorectal Cancer PHASE4UNKNOWN
Enhancing Effect on Tumour Apoptosis With the Use of Pentoxifylline in Patients With Hodgkin Lymphoma PHASE4UNKNOWN
Cyclophosphamide, Methotrexate, and Fluorouracil, With or Without Epirubicin Hydrochloride, in Treating Women Who Have Undergone Surgery for Breast Cancer (Group III Closed to New Patients as of 12/7/2009) PHASE3UNKNOWN
A Phase IIb Trial of Pulmicort Turbuhaler (Budesonide) PHASE2/PHASE3COMPLETED
Daunorubicin Hydrochloride, Cytarabine and Oblimersen Sodium in Treating Patients With Previously Untreated Acute Myeloid Leukemia PHASE3COMPLETED
Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL PHASE2RECRUITING
A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma PHASE2RECRUITING
Gossypol in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme PHASE2COMPLETED
Venetoclax + Azacitidine vs. Induction Chemotherapy in AML PHASE2ACTIVE_NOT_RECRUITING
Acetylsalicylic Acid and Eflornithine in Treating Patients at High Risk for Colorectal Cancer PHASE2COMPLETED
Ibrutinib + Venetoclax in Untreated WM PHASE2ACTIVE_NOT_RECRUITING
Bryostatin 1 and Cisplatin in Treating Patients With Advanced Recurrent or Residual Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer PHASE2COMPLETED
ACAPHA in Preventing Lung Cancer in Former Smokers With Bronchial Intraepithelial Neoplasia PHASE2COMPLETED
Venetoclax + Cytarabine Versus Idarubicin + Cytarabine : Efficacity Assessment as Post-remission Therapy to Elderly Patients With Acute Myeloid Leukemia in First Remission PHASE2ACTIVE_NOT_RECRUITING
Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN PHASE1ACTIVE_NOT_RECRUITING
Treating Patients With Advanced Solid Tumors, Breast Cancer or Recurrent Ovarian Cancer PHASE1COMPLETED
Gossypol (AT-101) and Temozolomide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme PHASE1COMPLETED
A Study of JNJ-74856665 in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) PHASE1COMPLETED
Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma PHASE1ACTIVE_NOT_RECRUITING
In Vivo Lithium Treatment Effects on Gene Expression Levels in Lymphoblastoid Cell Lines From Human Healthy Subjects PHASE1COMPLETED
Safe Accelerated Venetoclax Escalation in CLL PHASE1ACTIVE_NOT_RECRUITING
Smoking Influence on Apoptosis in Periodontitis nanCOMPLETED
Role of Sorcin and Annexin A3 in Breast Cancer Patients nanUNKNOWN
Clinical Study Protocol for the Treatment of ND-AML and RR-AML With KMT2A Gene Abnormalities Using VHEA. nanRECRUITING
Studying Cells Collected Through Ductal Lavage in Women Undergoing Surgery for Ductal Carcinoma In Situ or Other Breast Cancer nanCOMPLETED
Effect of Different Therapeutic Strategies on Regulatory T Cells in Kidney Transplantation nanCOMPLETED
Study of Biomarkers in Blood and Bone Marrow Samples From Patients With Previously Untreated Chronic Lymphocytic Leukemia nanCOMPLETED
The Effect of TRA-8 on Ovarian Cancer Tissue nanCOMPLETED
Immediate Allogeneic Hematopoietic Stem Cell Transplantation Versus Re-treatment for Patients With High-Risk Acute Myeloid Leukemia nanNOT_YET_RECRUITING

Related proteins — ESM-2 sequence neighbours (a BCL2 binder may also engage these)

ProteinNameSimilarity
O02718 — 1.000 O02718 →
P10417 — 1.000 P10417 →
Q6R755 — 0.999 Q6R755 →
P49950 — 0.999 P49950 →
Q9JJV8 — 0.998 Q9JJV8 →
Q00709 — 0.994 Q00709 →
BAK1 Bcl-2 homologous antagonist/killer 0.974 landscape →
Q5SNT2 — 0.972 Q5SNT2 →
P12755 — 0.972 P12755 →
P85299 — 0.969 P85299 →
Q9TUG2 — 0.969 Q9TUG2 →
Q8BXL9 — 0.969 Q8BXL9 →
Q812A5 — 0.969 Q812A5 →
Q2KJ58 — 0.968 Q2KJ58 →
Q5FVG6 — 0.968 Q5FVG6 →
Q80U62 — 0.968 Q80U62 →
A2SXS5 — 0.967 A2SXS5 →
A2A8U2 — 0.967 A2A8U2 →
Q8VDV3 — 0.967 Q8VDV3 →
Q0D2I5 — 0.967 Q0D2I5 →
Q6DVA0 — 0.967 Q6DVA0 →
Q8CC12 — 0.966 Q8CC12 →
Q8C190 — 0.966 Q8C190 →
Q60698 — 0.966 Q60698 →
A4D2P6 — 0.966 A4D2P6 →
Q9NUG4 — 0.966 Q9NUG4 →
ABHD16A Phosphatidylserine lipase ABHD16A 0.966 landscape →
NIBAN2 Protein Niban 2 0.965 landscape →
Q6NS60 — 0.965 Q6NS60 →
Q96CX2 — 0.965 Q96CX2 →